Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway

Background Prevention of metabolic complications of long‐term adjuvant endocrine therapy in breast cancers remained a challenge. We aimed to investigate the molecular mechanism in the development of tamoxifen (TAM)‐induced fatty liver in both estrogen receptor (ER)‐positive and ER‐negative breast cancer. Methods and results First, the direct protein targets (DPTs) of TAM were identified using DrugBank5.1.7. We found that mitogen‐activated...